- Home
- ELEV vs DRCT Comparison
ELEV vs DRCT Comparison
Compare ELEV & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- DRCT
- Stock Information
- Founded
- ELEV 2019
- DRCT 2018
- Country
- ELEV United States
- DRCT United States
- Employees
- ELEV N/A
- DRCT N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- ELEV Health Care
- DRCT Technology
- Exchange
- ELEV Nasdaq
- DRCT Nasdaq
- Market Cap
- ELEV 37.6M
- DRCT 38.7M
- IPO Year
- ELEV 2021
- DRCT 2022
- Fundamental
- Price
- ELEV $0.26
- DRCT $0.73
- Analyst Decision
- ELEV Buy
- DRCT Strong Buy
- Analyst Count
- ELEV 7
- DRCT 1
- Target Price
- ELEV $3.78
- DRCT $23.00
- AVG Volume (30 Days)
- ELEV 2.1M
- DRCT 1.4M
- Earning Date
- ELEV 03-06-2025
- DRCT 03-27-2025
- Dividend Yield
- ELEV N/A
- DRCT N/A
- EPS Growth
- ELEV N/A
- DRCT N/A
- EPS
- ELEV N/A
- DRCT N/A
- Revenue
- ELEV N/A
- DRCT $62,288,000.00
- Revenue This Year
- ELEV N/A
- DRCT N/A
- Revenue Next Year
- ELEV N/A
- DRCT $37.23
- P/E Ratio
- ELEV N/A
- DRCT N/A
- Revenue Growth
- ELEV N/A
- DRCT N/A
- 52 Week Low
- ELEV $0.24
- DRCT $0.51
- 52 Week High
- ELEV $5.83
- DRCT $14.86
- Technical
- Relative Strength Index (RSI)
- ELEV 23.65
- DRCT 43.42
- Support Level
- ELEV $0.24
- DRCT $0.74
- Resistance Level
- ELEV $0.55
- DRCT $1.46
- Average True Range (ATR)
- ELEV 0.04
- DRCT 0.14
- MACD
- ELEV -0.02
- DRCT 0.03
- Stochastic Oscillator
- ELEV 6.23
- DRCT 9.85
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.